Endo, Impax Schemed To Delay Opana Generics, Suit Says

Law360, New York (June 06, 2014, 3:00 PM ET) -- Endo Pharmaceuticals Inc. and Impax Laboratories Inc. were hit with a proposed antitrust class action in Pennsylvania federal court Wednesday alleging Endo paid Impax more than $112 million to delay generic versions of Endo's patented Opana ER painkiller from hitting the market.

Plaintiff Rochester Drug Cooperative Inc. accused Endo, as well as its subsidiary Penwest Pharmaceuticals Co., of crafting a scheme in which Endo paid Impax more than $112 million in cash in exchange for Impax agreeing to delay the launch of its cheaper, generic version...
To view the full article, register now.